If the traditional pharmacological approach keeps failing, why aren't the approaches that ARE working getting the investment, the coverage, and the clinical priority they deserve?
The Pipeline Isn't Just Dry—It's Collapsing
The wreckage is everywhere. NGF inhibitors, once the great hope for osteoarthritis and chronic low back pain, were derailed by rapidly progressive joint destruction. NK1 receptor antagonists and TRPV1 inhibitors showed beautiful results in rodents and failed in humans. Eli Lilly recently shelved two mid-stage pain programs. Acadia's novel redox modulator couldn't beat a placebo.
Even Suvetrigine (Journavx)—the first truly new painkiller approved in over two decades—comes with significant caveats. It's approved only for short-term acute pain. It failed to demonstrate superiority over an opioid-acetaminophen combination in secondary endpoints. And its Phase 2 trial for chronic sciatica? Failed to beat placebo. At roughly $15.50 per pill, it also carries significant cost barriers in a market dominated by generic alternatives.
The hard truth: the molecular, reductionist approach to chronic pain has a 99.3% failure rate. At what point do we stop doubling down on a strategy that isn't working?
What the Evidence Actually Tells Us
Interdisciplinary pain rehabilitation programs—integrating physical therapy, cognitive-behavioral therapy, operant therapy, and pain literacy counseling—show a minimum 15% improvement across all eight quality-of-life domains on the SF-36 compared with standard treatment. Beyond symptom relief, one landmark analysis found that patients in interdisciplinary programs generated $280 million less in medical costs the following year versus conventional care, with an additional $63 million saved in averted surgical costs.
Acupuncture, once dismissed as fringe, now carries robust meta-analytic evidence. Comprehensive analyses of over 2,100 participants show statistically significant advantages over oral medication in improving functional capacity (P < 0.00001). When added as an adjunct to standard therapy, acupuncture consistently outperforms standard therapy alone at both immediate and intermediate-term follow-ups.
On the frontier, psilocybin therapy is in Phase 2 trials for treatment-resistant fibromyalgia and chronic neuropathic pain, operating through mechanisms—neuroplasticity, default mode network disruption, reduced neuroinflammation—that address dimensions of chronic pain that conventional analgesics simply cannot reach. Stanford researchers have engineered a novel cannabinoid molecule that targets a previously unknown receptor pocket, delivering analgesia without psychoactive effects or tolerance development in preclinical models. Closed-loop neuromodulation systems are showing staggering efficacy: 72.6% of patients with chronic back pain achieved significant reduction, compared with just 7.1% under conservative medical management.
Every major clinical guideline body—the CDC, NICE, and IASP—explicitly recommends non-pharmacological therapies as first-line treatment. The AHRQ recognizes physical therapists, acupuncturists, chiropractors, and mind-body practitioners as essential providers of evidence-based pain management.
The evidence isn't the problem. So what is?
Follow the Money—and the Bias
The patent economy is the invisible hand. Because mindfulness, physical therapy, acupuncture, and botanical interventions can't be patented for 20-year monopolies, they hold zero commercial appeal to pharmaceutical companies or venture capital. In 2021, pain and addiction companies received just $228 million in venture capital—a mere 1.3% of total therapeutic VC. Oncology received $9.7 billion. That's a 270-to-1 funding disparity, despite comparable societal burden.
This creates a vicious cycle: without corporate funding, unpatentable therapies can't run the massive Phase 3 trials that insurers demand. Insurers then deny coverage, citing "lack of robust evidence." The system produces the very evidence gap it uses to justify exclusion.
Then there's the double standard of evidence itself. Opioids were historically approved based on short-term efficacy data. Yet alternative modalities face demands for long-term functional improvement, dose-response curves, and return-to-work metrics before payers will consider coverage. Complex interventions like CBT and acupuncture can't be easily double-blinded—and that methodological reality is used against them, even when their outcomes data are compelling.
The insurance architecture compounds the problem. A 30-day generic opioid prescription might cost a patient a $10 copay. An evidence-based course of physical therapy or acupuncture—12 sessions at $30–$50 each—can mean hundreds in out-of-pocket costs. Step therapy policies force patients to fail on cheaper, potentially addictive medications before authorizing comprehensive care. Original Medicare caps acupuncture at 20 visits per year, for chronic low back pain only, with a $283 deductible and 20% coinsurance. And in some states, coverage is actively being rolled back.
Finally, the education gap. Studies show that comprehensive pain education in medical school may amount to as little as 8 hours across four years. Multidisciplinary management, non-pharmacological approaches, the emotional dimensions of pain, treatment plan negotiation—all poorly taught or absent. Is it any surprise that primary care providers default to the prescription pad?
The Policy Horizon Is Shifting—But Not Fast Enough
The NIH HEAL Initiative is directing over $600 million annually toward pain and addiction research, with explicit prioritization of non-pharmacological treatments and pragmatic trials in underserved populations. The FDA has issued new draft guidance specifically for non-opioid chronic pain drug development and expanded streamlined pathways for novel pain devices.
These are significant steps. But policy without practice is just paper.
Crossing the Desert
What needs to change isn't just policy—it's practice. Providers need training and frameworks to operationalize the biopsychosocial model in real clinical settings, not just acknowledge it in theory. Patients need navigation support to access the evidence-based care that guidelines already recommend. And the healthcare system needs to align financial incentives with what the evidence has been telling us for years.
This is exactly the gap that Anodunos was built to address. Through the Anodunos Method, we're working to bridge the divide between what the evidence supports and what actually happens in clinical practice—equipping providers with the knowledge, frameworks, and tools to deliver truly integrated, whole-person chronic pain care, and empowering patients to navigate a system that too often fails them.
The 50 million Americans living with chronic pain can't wait for the next pharmaceutical miracle. They need us to act on what we already know works.
Nothing about us, without us.
The Pipeline Isn't Just Dry—It's Collapsing
Between 2017 and 2022, active clinical drug programs targeting pain dropped by 44%—from 220 programs to just 124. Novel chemical entity programs fell by 40%. Of the 220 programs active in 2017, 77% have since been suspended.
The wreckage is everywhere. NGF inhibitors, once the great hope for osteoarthritis and chronic low back pain, were derailed by rapidly progressive joint destruction. NK1 receptor antagonists and TRPV1 inhibitors showed beautiful results in rodents and failed in humans. Eli Lilly recently shelved two mid-stage pain programs. Acadia's novel redox modulator couldn't beat a placebo.
Even Suvetrigine (Journavx)—the first truly new painkiller approved in over two decades—comes with significant caveats. It's approved only for short-term acute pain. It failed to demonstrate superiority over an opioid-acetaminophen combination in secondary endpoints. And its Phase 2 trial for chronic sciatica? Failed to beat placebo. At roughly $15.50 per pill, it also carries significant cost barriers in a market dominated by generic alternatives.
The hard truth: the molecular, reductionist approach to chronic pain has a 99.3% failure rate. At what point do we stop doubling down on a strategy that isn't working?
What the Evidence Actually Tells Us
While the pharma pipeline has been hemorrhaging failures, alternative, complementary, and multidisciplinary approaches have been quietly building an impressive evidence base.
Interdisciplinary pain rehabilitation programs—integrating physical therapy, cognitive-behavioral therapy, operant therapy, and pain literacy counseling—show a minimum 15% improvement across all eight quality-of-life domains on the SF-36 compared with standard treatment. Beyond symptom relief, one landmark analysis found that patients in interdisciplinary programs generated $280 million less in medical costs the following year versus conventional care, with an additional $63 million saved in averted surgical costs.
Acupuncture, once dismissed as fringe, now carries robust meta-analytic evidence. Comprehensive analyses of over 2,100 participants show statistically significant advantages over oral medication in improving functional capacity (P < 0.00001). When added as an adjunct to standard therapy, acupuncture consistently outperforms standard therapy alone at both immediate and intermediate-term follow-ups.
On the frontier, psilocybin therapy is in Phase 2 trials for treatment-resistant fibromyalgia and chronic neuropathic pain, operating through mechanisms—neuroplasticity, default mode network disruption, reduced neuroinflammation—that address dimensions of chronic pain that conventional analgesics simply cannot reach. Stanford researchers have engineered a novel cannabinoid molecule that targets a previously unknown receptor pocket, delivering analgesia without psychoactive effects or tolerance development in preclinical models. Closed-loop neuromodulation systems are showing staggering efficacy: 72.6% of patients with chronic back pain achieved significant reduction, compared with just 7.1% under conservative medical management.
Every major clinical guideline body—the CDC, NICE, and IASP—explicitly recommends non-pharmacological therapies as first-line treatment. The AHRQ recognizes physical therapists, acupuncturists, chiropractors, and mind-body practitioners as essential providers of evidence-based pain management.
The evidence isn't the problem. So what is?
Follow the Money—and the Bias
The barriers keeping evidence-based alternatives from first-line status are structural, financial, and cultural. And they're interconnected.
The patent economy is the invisible hand. Because mindfulness, physical therapy, acupuncture, and botanical interventions can't be patented for 20-year monopolies, they hold zero commercial appeal to pharmaceutical companies or venture capital. In 2021, pain and addiction companies received just $228 million in venture capital—a mere 1.3% of total therapeutic VC. Oncology received $9.7 billion. That's a 270-to-1 funding disparity, despite comparable societal burden.
This creates a vicious cycle: without corporate funding, unpatentable therapies can't run the massive Phase 3 trials that insurers demand. Insurers then deny coverage, citing "lack of robust evidence." The system produces the very evidence gap it uses to justify exclusion.
Then there's the double standard of evidence itself. Opioids were historically approved based on short-term efficacy data. Yet alternative modalities face demands for long-term functional improvement, dose-response curves, and return-to-work metrics before payers will consider coverage. Complex interventions like CBT and acupuncture can't be easily double-blinded—and that methodological reality is used against them, even when their outcomes data are compelling.
The insurance architecture compounds the problem. A 30-day generic opioid prescription might cost a patient a $10 copay. An evidence-based course of physical therapy or acupuncture—12 sessions at $30–$50 each—can mean hundreds in out-of-pocket costs. Step therapy policies force patients to fail on cheaper, potentially addictive medications before authorizing comprehensive care. Original Medicare caps acupuncture at 20 visits per year, for chronic low back pain only, with a $283 deductible and 20% coinsurance. And in some states, coverage is actively being rolled back.
Finally, the education gap. Studies show that comprehensive pain education in medical school may amount to as little as 8 hours across four years. Multidisciplinary management, non-pharmacological approaches, the emotional dimensions of pain, treatment plan negotiation—all poorly taught or absent. Is it any surprise that primary care providers default to the prescription pad?
The Policy Horizon Is Shifting—But Not Fast Enough
There are real reasons for cautious optimism. CMS has introduced dedicated chronic pain management billing codes (G3002/G3003) that reimburse providers for the time-intensive work of biopsychosocial assessment and care coordination. The NOPAIN Act, effective January 2025, now provides separate reimbursement for non-opioid analgesics in outpatient surgical settings. The ACCESS value-based care model, launching its performance period in July 2026, will reimburse digital health tools, wearables, and patient education applications for chronic conditions.
The NIH HEAL Initiative is directing over $600 million annually toward pain and addiction research, with explicit prioritization of non-pharmacological treatments and pragmatic trials in underserved populations. The FDA has issued new draft guidance specifically for non-opioid chronic pain drug development and expanded streamlined pathways for novel pain devices.
These are significant steps. But policy without practice is just paper.
Crossing the Desert
The path forward requires us to be honest about where we are. We have spent decades and billions searching for the next blockbuster molecule while systematically undervaluing and underfunding the multimodal approaches that actually address the biopsychosocial complexity of chronic pain.
What needs to change isn't just policy—it's practice. Providers need training and frameworks to operationalize the biopsychosocial model in real clinical settings, not just acknowledge it in theory. Patients need navigation support to access the evidence-based care that guidelines already recommend. And the healthcare system needs to align financial incentives with what the evidence has been telling us for years.
This is exactly the gap that Anodunos was built to address. Through the Anodunos Method, we're working to bridge the divide between what the evidence supports and what actually happens in clinical practice—equipping providers with the knowledge, frameworks, and tools to deliver truly integrated, whole-person chronic pain care, and empowering patients to navigate a system that too often fails them.
The 50 million Americans living with chronic pain can't wait for the next pharmaceutical miracle. They need us to act on what we already know works.
Nothing about us, without us.
The Anodunos Method
Quick links
Created with
